Role of Glucagon-like Peptide-1 (GLP-1) receptor agonists versus DPP-4 inhibitors for alcohol and substance use disorders in improving HIV-related outcomes and providing health benefits in people living with HIV
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The National Institute on Drug Abuse (NIDA) and National Institute on Alcohol Abuse and Alcoholism (NIAAA) are conducting a Small Business Sources Sought to identify qualified small businesses for a pharmacoepidemiological study. This research focuses on the Role of Glucagon-like Peptide-1 (GLP-1) receptor agonists versus DPP-4 inhibitors for alcohol and substance use disorders in improving HIV-related outcomes and providing health benefits in people living with HIV. Responses are due by May 6, 2026, 5:00 PM EST.
Scope of Work
This notice seeks vendors capable of conducting high-quality pharmacoepidemiological studies. The project involves examining GLP-1RAs and their potential health benefits for people living with HIV (PLWH) with comorbid alcohol and substance use disorders (ASUDs). Using electronic health record data from the Department of Veterans Affairs (VA), specifically the Veterans Aging Cohort Study (VACS), the vendor will investigate the association between GLP-1RAs (prescribed for any indication) and HIV- and ASUD-related outcomes. This includes assessing improvements in HIV-related biomarkers (HIV RNA, CD4 count), ART retention, liver function, physical health, physiological frailty, and pain levels.
Key Requirements
Capable offerors must demonstrate experience with:
- Robust pharmacoepidemiology analyses involving ASUD and HIV-related outcomes.
- Identifying early efficacy signals with medications.
- Data extraction, management, analysis, and reporting of propensity-score matched pharmacoepidemiological studies.
- Managing de-identified data.
- Pulling, organizing, and cleaning specific datasets.
- Applying approaches consistent with data science in biomedical research and cutting-edge pharmacoepidemiologic methods.
- Mandatory: Full access to VACS data and an already built data analysis pipeline.
Contract & Timeline
- Type: Sources Sought / Market Research (not a solicitation)
- Potential Duration: Anticipated 12-month base period with three (3) 12-month option periods for a future contract.
- Set-Aside: Specifically for Small Businesses.
- Response Due: May 6, 2026, 5:00 PM EST
- Published: April 21, 2026
Submission Details
Interested small businesses must submit a capability statement electronically to Kimberly Harris (Kimberly.harris2@nih.gov) in MS Word or PDF format. The email subject line must be "75N95026R00007". The statement must specifically address each project requirement and include:
- Total number of employees.
- Professional qualifications of personnel.
- Any relevant GSA Schedule contracts or GWACs.
- Company Name, Unique Entity ID (SAM.gov), Physical Address, and Point of Contact Information.
- Business type, applicable NAICS code, and size standards.
Additional Notes
This is for research and information purposes only; it is not a commitment to issue a solicitation or award a contract. No award will be made as a result of this notice, and the Government will not be responsible for any costs incurred by respondents. Proprietary, classified, confidential, or sensitive information should not be included.